Our People
Managing Director
Mrs. Sirisha.S, M.B.A., Mrs. Sirisha has been managing director of Sadashiva Life Sciences since 2020. She has over 15 years' experience in the pharmaceutical and biotechnology industries, specializing in APIs and formulations...
Chief Executive Officer & Director
Mr. Rajesh Mudireddy is the chief executive officer and a director of Sadashiva Life Sciences. He has played a crucial role in the company's growth and strategy over the past two years...
Director
Mrs. Harini Ganga, B.Tech., Mrs. Harini has been a director of Sadashiva Life Sciences since 2020. She is currently serving as the director, head of finance and marketing for Sitara Infrastructure Pvt Ltd, a Hyderabad-based developer ...
Our People
Scientific Advisory Board
Dr. Rajesh.Medisetty has over twenty years of experience in the research and biopharmaceutical industry, specializing in biosimilars, complex generics, and vaccine development ....
Deputy General Manager, R&D
Dr. Munikishore Rachakunta has been deputy general manager, Research and Development at Sadashiva Life Sciences since August 2022. Prior to his appointment, Dr. Rachakunta was a member ....
Scientific Advisory Board
Dr. Venkat has over eight years of extensive experience in the pharmaceutical industry analysing and characterizing proteins, natural products, drug metabolites, impurities and degradation products using mass spectrometry...
Scientific Advisory Board
Dr. Abdul-Qadeer has 10 years of diverse experience in pharmaceutical and health care companies, specializing in biochemistry, immunology, protein chemistry, and molecular cell biology...
Mrs. Sirisha.S, M.B.A., Mrs. Sirisha has been managing director of Sadashiva Life Sciences since 2020. She has over 15 years' experience in the pharmaceutical and biotechnology industries, specializing in APIs and formulations. She also sits on the board of directors and is a member of the scientific advisory board. During her last two years at Sadashiva, Mrs. Sirisha played a pivotal role in developing the company through licensing and acquisitions, international expansion, and emerging markets strategies. She received her master’s degree in finance with a gold medal from Jawaharlal Nehru Technological University (JNTU), Hyderabad, India.
Mr. Rajesh Mudireddy is the chief executive officer and a director of Sadashiva Life Sciences. He has played a crucial role in the company's growth and strategy over the past two years. Prior to this, Mr. Rajesh was in a senior position at Biological E Ltd, where he made noteworthy contributions to the development of Low-molecular-weight heparins (LMWHs), from the initial stages to production. Mr.Rajesh brings nearly two decades of Analytical R&D, APIs, CRAMPS, Drug discovery, new molecule development, and regulatory compliance experience from reputed companies such as Hetero drugs, GVK-Bio, and Biological E Ltd. Mr.Rajesh started his industrial career at Hetero Drugs and held leadership roles in corporate development and strategy at E-Infinity Software Solutions. He holds bachelor and master degrees in organic chemistry from Osmania University and Acharya Nagarjuna University, respectively.
Mrs. Harini Ganga, B.Tech., Mrs. Harini has been a director of Sadashiva Life Sciences since 2020. She is currently serving as the director, head of finance and marketing for Sitara Infrastructure Pvt Ltd, a Hyderabad-based developer engaged in real estate activities in the southern part of the country. Prior thereto, from 2016 to 2019, she served in a senior position at Franklin Resources, Inc. (also well known as Franklin Templeton), an American multinational investment firm. She graduated with a gold medal in computer sciences from Mahatma Gandhi Institute of Technology (MGIT), which is affiliated with Jawaharlal Nehru Technological University (JNTU), Hyderabad, India.
Dr. Rajesh.Medisetty has over twenty years of experience in the research and biopharmaceutical industry, specializing in biosimilars, complex generics, and vaccine development. Over the course of his career, he has held numerous leadership roles that have contributed to the advancement of biologics, biosimilars, and complex generics. He has managed teams of scientists with expertise in microorganisms and mammals, monoclonal antibodies (mAbs), non-mAbs, insulin analogs, and more. It has been a highlight of his career to play a significant role in the acceptance of complex generics in the USA, Canada, Brazil, Europe, and other parts of the world. As a product development expert, he handles all aspects of product development, including tech transfer, scaling up, process validation, and global regulatory filings. Having demonstrated a strong understanding of GLP and GMP standards, he played a pivotal role in successful US FDA audits of both R&D and manufacturing units. Currently, he serves as President and Head of Research and Development for Shilpa Biologicals Pvt Ltd, where he oversees product portfolios, budget approval, recruitment of talent, and biosimilar and generic product development. Additionally, he has demonstrated leadership capabilities in previous positions such as Senior Vice President at Dandu Biosciences Pvt Ltd and General Manager at Biological E Limited, where he coordinated large teams, developed and executed strategic plans, and managed successful projects. He brings a wealth of experience in managerial responsibilities, including talent screening, selection, and retention, as well as motivating teams to achieve milestones. Aside from his technical expertise, he brings a wealth of experience in managerial responsibilities, such as talent screening, selection, and retention, as well as motivating teams. He is experienced in answering regulatory queries, supporting dossier preparation, and ensuring regulatory approval. A Ph.D. graduate with postdoctoral experience has contributions to the scientific community in the form of several patents related to in-vitro methods for determining the fate of polypeptide variants, the identification of polypeptide variants, and the assessment of protein isoforms that were modified post-translationally. Overall, a great leader with multifaceted expertise, leadership acumen, and significant contributions to the biopharmaceutical industry. As a result, he is a dynamic professional capable of driving innovation and success through research and development.
Dr. Munikishore Rachakunta has been deputy general manager, Research and Development at Sadashiva Life Sciences since August 2022. Prior to his appointment, Dr. Rachakunta was a member of the scientific advisory board of Sadashiva Life Sciences, which provides advice to the Company’s management team since October 2019. He has more than 6 years of experience in the Biotech/Pharma industry and has a strong background in new drug discovery, development and the acquisition of new drug candidates and other technologies. Prior thereto, from 2019 to 2022, Dr. Rachakunta was a Postdoctoral associate at Chinese Academy of Sciences (CAS), China, where he led the projects on discovering and developing Cathepsin L protein degradation using modern technology, Proteolysis targeting chimeras (PROTACs), and Cav 3.2 calcium channel inhibitors derived from Cyclovirobuxine D, a natural drug substance. Previously, Dr. Rachakunta worked for Biological E Ltd as an analytical research and development scientist, developing and validating various methods for drug substances and products. As a senior scientist at ISCA Technologies (formerly ATGC Biotech Private Limited, Hyderabad, India), he transferred technology and manufactured insect pheromones for commercial purposes. He received his Bachelor, Master, MPhil, and Ph.D. degrees in chemistry from Sri Venkateswara University, India. He has authored more than 15 original research articles and is listed as an inventor on patents related to cardiovascular and cancer drug discovery. Moreover, he serves as an editorial member for reputable journals. He is also a member of several chemical societies, including the American Chemical Society, Royal Society of Chemistry, and American Botanical Council.
Dr. Venkat has over eight years of extensive experience in the pharmaceutical industry analysing and characterizing proteins, natural products, drug metabolites, impurities, and degradation products using mass spectrometry. In his current role as a senior scientist at Dr Reddy's laboratory in Hyderabad, he led the project on quantitative and qualitative analysis of leachable and Genotoxic impurities (GTIs). Prior to Dr. Reddy's, Dr.Venkat served as a senior manager in the characterization division of Biological E Ltd for four years. In this role, Dr. Venkat developed various methods for the characterization of carbohydrates (Glycans), glycosaminoglycans (GAGs), and small molecules in complex systems. Dr. Venkat began his industrial career with Aptuit Laurus Private Ltd, India, where he gained extensive exposure to analytical studies. Dr. Venkat earned his doctorate in synthetic organic chemistry from the Indian Institute of Technology (IIT), Roorkee, India and completed postdoctoral training at the Indian Institute of Technology (IIT), Bombay, India. Moreover, he holds a master's degree in chemistry from GITAM College, Vizag, India, has published several scientific papers in peer-reviewed journals, and has served as a reviewer for reputed journals specializing in mass spectrometry.
Dr. Abdul-Qadeer has 10 years of diverse experience in pharmaceutical and health care companies, specializing in biochemistry, immunology, protein chemistry, and molecular cell biology. His current position is Assistant General Manager at Biological E Ltd, where he is responsible for developing bioassays, characterization, potency-based assays, and drug-protein interactions for peptides, insulin analogs, and complex generics for the past five years. He acted as a consultant research scientist at Cytocare Technologies Private Limited, Hyderabad, India. He also served as faculty and guest faculty in two colleges affiliated with Osmania University, for about 5 years. His academic research focused on protein chemistry, cancer biology, and the development of preclinical models. He published his findings in various journals. He holds a B.Sc in Microbiology, M.Sc in Biotechnology, a Ph. D in Biochemistry from Osmania University and completed his post-doctoral research at Roswell Park Cancer Research Institute, NY, USA.
